Medicine
Relpax 40 mg tablet
Relpax 40 mg tablet is a prescription medicine containing Eletriptan for oral use, marketed by Viatris Specialty, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C to…
Key facts
- Active ingredient (INN)
- Eletriptan
- Brand
- Relpax
- Strength
- 40 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 6 blister pack, 12 blister pack
- Marketing authorisation holder
- Viatris Specialty
- Manufacturer
- Viatris Specialty
- Origin register
- US FDA, United States
- Storage
- Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C to 30°C (59°F to 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- N02CC06 Eletriptan
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 21 August 2024
- Identifiers
- RxCUI 359493, 359494, 404443 +1DailyMed set ID 2a501dbd-3ea8-47e4-9fcb-07035b8c8c9eNDC 58151-368Application NDA021016
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 6 blister pack in 1 carton / 1 tablet in 1 blister pack | 58151-368-56 | Viatris Specialty | 21 August 2024 |
| 12 blister pack in 1 carton / 1 tablet in 1 blister pack | 58151-368-96 | Viatris Specialty | 23 January 2025 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 26 December 2002 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Eletriptan 40 mg tablet.
Other strengths and forms of Eletriptan
Clinical summary
Eletriptan is a serotonin-1b and serotonin-1d receptor agonist indicated for the acute treatment of migraine with or without aura in adults, among other approved uses. It is available as tablets for oral use. MedsAcross supplies Eletriptan for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about EletriptanFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Relpax prescribing information (Viatris Specialty) · U.S. National Library of Medicine, DailyMed
Need Relpax 40 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.